An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

NCT03897881 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: mRNA-4157
BIOLOGICAL: Pembrolizumab

Sponsor

ModernaTX, Inc.

Collaborators

[object Object]